. 2013 Nov 22;116(2):395–404. doi: 10.1007/s11060-013-1311-3

Table 4.

The outcomes of selected series of GBMO and GBM

Author	Patient group	Number of patients	Treatment	Median OS (months)	P value
Miller et al. [2]	AOA with necrosis	71	N/A	22.8
Miller et al. [2]	GBM	581	N/A	9.8	<0.0001*
Vordermark et al. [1]	GBMO	10	Post-OPT RT in 90 % + ACNU and VM26 in 80 %	26.0	N/A
Kanno et al. [3]	GBMO	17	Post-OPT RT + ACNU + TMZ	≈40.0^a
Kanno et al. [3]	GBM	52	Post-OPT RT + ACNU + TMZ	≈18.0^a	0.068
Jiang et al. [10]	GBMO	40	Post-OPT RT in 85 %; RT + Chemo in 62 %	19.0
Jiang et al. [10]	GBM	179	Post-OPT RT in 87 %; RT + Chemo in 65 %	13.2	0.022*
Pinto et al. [4]	GBMO	24	Post-OPT RT + Chemo	14.9
Pinto et al. [4]	GBM	64	Post-OPT RT + Chemo	13.5	0.566
Hegi et al. [5]	GBMO	52	Post-OPT RT + Concomitant TMZ + Ajuvand TMZ	N/A
Hegi et al. [5]	GBM	287	Post-OPT RT + Concomitant TMZ + Ajuvand TMZ	N/A	0.48
Nakamura et al. [6]	GBMO	19	Post-OPT RT in 100 % + ACNU/TMZ in 89.5 %	14.0	N/A
Present study	GBMO-STS	11	Post-OPT RT in 100 % + ACNU in 100 % + TMZ in 63.6 %	10.0
	GBMO-LTS	29	Post-OPT RT in 96.6 % + ACNU in 89.7 % + TMZ in 72.4 %	18.5
	GBM	110	Post-OPT RT in 92.7 % + ACNU in 96.4 % + TMZ in 53.6 %	16.0	<0.001*

^aEstimated value from graph

OPT operation, RT radiation therapy, Chemo chemotherapy, ACNU nimustine, TMZ temozolomide, N/A not available